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Background
It has been demonstrated by several groups that the use of
rBCG expressing HIV immunogens is a good priming vec-
tor for vaccinia based HIV vaccines, mainly in the preven-
tion of mother-to-child HIV transmission. Our group has
shown in Balb/C mice that rBCG:HIVA can both prime
novel and boost preexisting HIV-1 specific cellular
immune responses. In this study we have evaluated the
HIV specific cellular immune responses induced after
newborn and adult mice immunization using different
routes with rBCG:HIVA prime and MVA:HIVA boost.
Methods
We have inoculated 106cfu of rBCG:HIVA to adult mice (7
weeks old) by intradermal and subcutaneous route, and 2
× 106 cfu to newborn mice (7 days old) by subcutaneous
route. 106 pfu of MVA:HIVA was inoculated intramuscu-
larly at 14 weeks post-BCG inoculation, and 3 weeks later
the animals were sacrificed. The specific HIV cellular
immune responses were analyzed in spleen cells by Intra-
cellular cytokine staining (ICS) and in vitro CTL activity.
The body weight of the newborn mice was weekly
recorded.
Results
The frequencies of HIV-specific CD8+ T-cells producing
IFN-γ was higher in adult mice vaccinated intradermally
(2.18%) and lower in adult (1,02%) and newborn mice
(0,59%) vaccinated subcutaneously. In all cases the IFN-γ
production was significantly higher when mice were
primed with rBCG:HIVA compared with BCGwt. When
the HIV specific CTL activity was assessed, no clear differ-
ence was observed between intradermal and subcutane-
ous route in adult mice, but the frequencies of specific
killing were higher in newborn mice than in adults. The
prime-boost vaccination regimen which includes
rBCG:HIVA and MVA:HIVA was safe when inoculated to
newborn mice. No differences in body weight evolution
were observed.
Conclusion
The administration of rBCG:HIVA to newborn mice is safe
and immunogenic and increased the HIV-specific
responses induced by MVA:HIVA vaccine. It might be a
good model for infant HIV and tuberculosis bivalent vac-
cine.
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